Finance

Lists
Outlook: 23.1% bullish·0.0% bearish
Go to analysis
KVUE:NYSE
Kenvue Inc
$18.90
-0.08%
(-0.015) 1D
Oct 19, 3:09:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KVUE...
Open
$18.70
High
$18.92
Low
$18.66
Mkt. cap
36.31B
Avg. vol.
24.92M
Volume
5.88M
Dividend
4.45%
Quarterly dividend
$0.21
Ex-dividend date
Sep 21, 2026
P/E ratio
21.91
52-wk high
$20.13
52-wk low
$14.02
EPS
$0.86
Beta
0.48
Shares outstanding
1.92B
No. of employees
22K
Open
$18.70
High
$18.92
Low
$18.66
Mkt. cap
36.31B
Avg. vol.
24.92M
Volume
5.88M
Dividend
4.45%
Quarterly dividend
$0.21
Ex-dividend date
Sep 21, 2026
P/E ratio
21.91
52-wk high
$20.13
52-wk low
$14.02
EPS
$0.86
Beta
0.48
Shares outstanding
1.92B
No. of employees
22K
News stories
From web sources and news partners
Profile
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
About Kenvue Inc
CEOKirk Perry
Employees21.9K
Founded2022
HeadquartersSummit, New Jersey, United States
SectorPersonal care products
Websitekenvue.com
Analyst ratings
Based on 7 analysts giving stock ratings to KVUE in the past 3 months
Hold
Buy
1
Hold
6
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for KVUE in the last 3 months.
Highest
Current $18.90
$20.00 (+5.85%)
Average
$19.25 (+1.88%)
Lowest
$19.00 (+0.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Peter Grom
UBS
Hold
Maintained
$19.00
+0.6%
10/15/2026
Filippo Falorni
Citi
Hold
Maintained
$19.00
+0.6%
10/14/2026
Susan Anderson
Canaccord Genuity
Buy
Maintained
-
-
09/16/2026
Taylor Conrad
Argus Research
Hold
Maintained
-
-
09/14/2026
Nik Modi
RBC Capital
Hold
Maintained
$20.00
+5.8%
08/07/2026
Jon Andersen
William Blair
Hold
Maintained
-
-
08/06/2026
Lauren Lieberman
Barclays
Hold
Maintained
$19.00
+0.6%
08/06/2026
Javier Escalante
Evercore ISI
Hold
Maintained
$18.00
-4.7%
02/18/2026
Keith Devas
Jefferies
Hold
Downgraded
$18.00
-4.7%
01/30/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
$0.31 / $0.32
-2.82%miss
Revenue / Est. (USD)
3.96B / 3.97B
-0.36%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.76B
3.78B
3.91B
3.96B
Cost of goods sold
1.53B
1.63B
1.60B
1.64B
Cost of revenue
1.53B
1.63B
1.60B
1.64B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.51B
1.51B
1.45B
1.54B
Operating expense
1.51B
1.48B
1.46B
1.54B
Total operating expenses
3.04B
3.11B
3.06B
3.19B
Operating income
726.00M
674.00M
845.00M
768.00M
Other non operating income
10.00M
7.00M
-
1.00M
EBT including unusual items
526.00M
427.00M
672.00M
598.00M
EBT excluding unusual items
623.00M
574.00M
750.00M
667.00M
Income tax expense
128.00M
97.00M
198.00M
142.00M
Effective tax rate
24.33%
22.72%
29.46%
23.75%
Other operating expenses
1.00M
-30.00M
11.00M
6.00M
Net income
398.00M
330.00M
474.00M
456.00M
Net profit margin
10.57%
8.73%
12.13%
11.53%
Earnings per share
0.28
0.27
0.32
0.31
Interest and investment income
14.00M
11.00M
11.00M
13.00M
Interest expense
-107.00M
-109.00M
-106.00M
-103.00M
Net interest expenses
-93.00M
-98.00M
-95.00M
-90.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
867.00M
713.00M
988.00M
913.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps